Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nuclear factor erythroid 2 related factor 2, tumor necrosis factor alpha, interleukin-40, and endorepellin levels in patients undergoing coronary artery bypass grafting.

Revista da Associacao Medica Brasileira (1992)·2026
Same author

The Molecular Relationship Between SDF4 and Thiol/Disulfide Homeostasis and Cardiac Injury Markers in Serum and Pericardial Fluid of Patients Undergoing Open-Heart Surgery.

Journal of clinical medicine·2025
Same author

Comparison of dynamic thiol/disulfide homeostasis in percutaneous nephrolithotomy and retrograde intrarenal surgery.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica·2025
Same author

Evaluation of Nrf2/Keap1 Pathway in Patients with Migraine.

Medicina (Kaunas, Lithuania)·2025
Same author

A Pilot Study on the Dual Role of ADAMTS-1, -4, and -5 in Necrotizing Enterocolitis: Linking Tissue Pathology and Serum Biomarker Discovery.

American journal of perinatology·2025
Same author

Comparative Investigation of Cardiac Injury Mediated by IL-40 and Oxidative Stress Markers in Pericardial Fluid and Serum.

Medicina (Kaunas, Lithuania)·2025

Related Experiment Video

Updated: Mar 14, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.7K

CA IX Inhibition by a Sulfonamide Compound: A Therapeutic Approach Against Breast Cancer.

Sükrü Akmese1, Ebru Temiz2, Elif Gürel3

  • 1Department of Medicinal Biochemistry, Medical Faculty, Harran University, Sanlıurfa, Turkey.

Chemistry & Biodiversity
|March 13, 2026
PubMed
Summary

This study shows that the sulfonamide derivative MMH-I effectively targets carbonic anhydrase IX (CA IX) in breast cancer models. MMH-I reduced tumor growth and promoted cancer cell death, indicating its potential as a novel therapeutic agent.

Keywords:
4T1 Cancer Modelapoptosisbreast cancercarbonic anhydrase IXsulfonamide

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
07:53

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

7.8K

Related Experiment Videos

Last Updated: Mar 14, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.7K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
07:53

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

7.8K

Area of Science:

  • Oncology
  • Biochemistry
  • Pharmacology

Background:

  • Carbonic anhydrase IX (CA IX) is a key enzyme overexpressed in solid tumors, driving cancer progression.
  • Sulfonamide derivatives are investigated as potential CA IX inhibitors for cancer therapy.

Purpose of the Study:

  • To evaluate the anticancer potential and therapeutic efficacy of the sulfonamide derivative MMH-I.
  • To assess MMH-I's CA IX-targeted activity in vitro and in vivo breast cancer models.

Main Methods:

  • Cytotoxicity assessed by MTT assays; apoptosis evaluated by acridine orange/ethidium bromide staining and Annexin V detection.
  • In vivo studies included tumor volume measurement, CA IX, Vimentin, E-Cadherin, Caspase-3 analysis, H&E staining, and plasma metabolomics.

Main Results:

  • MMH-I significantly reduced tumor volume and induced apoptosis in breast cancer cells.
  • The compound altered expression of cancer-related genes and metabolic profiles, with notable changes in CA IX, Vimentin, E-Cadherin, and Caspase-3 levels.

Conclusions:

  • MMH-I demonstrates significant anticancer activity and CA IX-targeting potential in preclinical breast cancer models.
  • MMH-I warrants further investigation as a therapeutic candidate, potentially in combination strategies for hypoxic tumors.